Your prediction
Pros and Cons of Advanced Proteome Therapeutics in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Advanced Proteome Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | - | - | - | - | - | - | - |
| Northwest Biotherapeutics Inc. | - | 38.462% | 12.500% | -15.888% | -12.621% | -59.641% | -81.910% |
| Larimar Therapeutics Inc. | -2.140% | 5.172% | 11.585% | 17.308% | 10.241% | 4.571% | -66.727% |
| Achieve Life Sciences Inc. | 8.770% | 8.772% | 16.981% | 191.080% | 67.568% | 29.167% | -13.889% |
News
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
Key Points
- Interested in Ocugen, Inc.? Here are five stocks we like better.
- Ocugen is targeting 2027 BLA filings for its OCU400 retinitis pigmentosa and OCU410ST Stargardt disease gene
JFrog Says AI Software Boom, Cloud Demand and Security Adoption Are Fueling Growth
Key Points
- Interested in JFrog Ltd.? Here are five stocks we like better.
- JFrog reported strong growth, including 29% overall revenue growth and 53% cloud-revenue growth, driven by higher
Lumexa Imaging Q2 Earnings Call Highlights
Key Points
- Interested in Lumexa Imaging Holdings, Inc.? Here are five stocks we like better.
- Lumexa returned to profitability in Q2: Revenue rose 5.1% year over year to $264.2 million, net